Tienda Elsevier

¿Aún no está registrado?

Información relevante

Consulte los artículos y contenidos publicados en éste medio, además de los e-sumarios de las revistas científicas en el mismo momento de publicación

Máxima actualización

Esté informado en todo momento gracias a las alertas y novedades

Promociones exclusivas

Acceda a promociones exclusivas en suscripciones, lanzamientos y cursos acreditados

Crear Mi cuenta

* = Required fields

Enter your email address

User name *

Annals of Hepatology

Annals of Hepatology Most often read

Annals of Hepatology

ISSN: 1665-2681

Annals of Hepatology (AoH) is an international, open access journal published bi-monthly with funds from the Fundación Clínica Médica Sur. It is the official journal of the Mexican Association of Hepatology (AMH), the Latin American Association for the Study of the Liver (ALEH), the Canadian Association for the Study of the Liver (CASL) and the Czech Society of Hepatology (CSH). AoH publishes editorials, opinions, concise reviews, original articles, brief reports, letters to the editor, news from affiliated associations, clinical practice guidelines and summaries of congresses in the field of Hepatology.

Topics covered by AoH include alcoholic liver disease, autoimmune hepatitis, biliary diseases, drug-induced liver injury, genetic liver diseases, NAFLD/NASH and viral hepatitis (HAV, HBV, HCV, HDV, HEV). Our journal seeks to publish articles on basic clinical care and translational research focused on preventing rather than treating the complications of end-stage liver disease.

See more Open Access Option

Indexed in:

Scopus, Medline, Directory of Open Access Journals (DOAJ), Science Citation Index Expanded (SCIE), SCImago Journal Rank (SJR), SNIP

See more

Follow us:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2025

See more

Impact factor 2024

4.4

Citescore

CiteScore measures average citations received per document published.

See more

Citescore 2024

9.1

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

See more

SJR 2024

1.011

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

See more

SNIP 2024

1.057

View more metrics

Journal Information

Most often read

Vol. 31. Issue. 1

29087

Updated recommendations for the management of metabolic dysfunction–associated steatotic liver disease (MASLD) by the Latin American working group

Luis Antonio Diaz, Juan Pablo Arab, Francisco Idalsoaga, Javiera Perelli, Javier Vega, Melisa Dirchwolf, Javiera Carreño, Bárbara Samith, ... Mario G. Pessoa

Ann Hepatol. 2025;30:101903

29087

Full text access

Share

10366

Treatment for hepatocellular carcinoma after immunotherapy

Landon L. Chan, Tsz Tung Kwong, Johnny C.W. Yau, Stephen L. Chan

Ann Hepatol. 2025;30:101781

10366

Full text access

Share

9004

Is the liver resilient to the process of ageing?

Nirupama Chatterjee, Rishabh Sharma, Pratibha R Kale, Nirupma Trehanpati, Gayatri Ramakrishna

Ann Hepatol. 2025;30:101580

9004

Full text access

Share

7226

Does the hepatologist still need to rely on aminotransferases in clinical practice? A reappraisal of the role of a classic biomarker in the diagnosis and clinical management of chronic liver diseases

Patrizia Burra, Calogero Cammà, Pietro Invernizzi, Fabio Marra, Maurizio Pompili

Ann Hepatol. 2025;30:101900

7226

Full text access

Share

6109

Soft drink consumption and increased risk of nonalcoholic fatty liver disease: Results from the health workers cohort study

Edgar Denova-Gutiérrez, Berenice Rivera-Paredez, Amado D. Quezada-Sánchez, Brianda I. Armenta-Guirado, Paloma Muñoz-Aguirre, Yvonne N. Flores, Rafael Velázquez-Cruz, Jorge Salmerón

Ann Hepatol. 2025;30:101566

6109

Full text access

Share

5850

Chronic hepatitis B virus persistence: Mechanisms, consequences and implications for achieving cure

Christopher Georgi, Simmone D’Souza, Carla Osiowy, Carla S. Coffin, Curtis L. Cooper

Ann Hepatol. 2025;30:101938

5850

Full text access

Share

4966

A comprehensive meta-analysis of stem cell therapy for liver failure: Assessing treatment efficacy and modality

Shenglong Lin, Haibing Gao, Huaxi Ma, Ziyuan Liao, Dongqing Zhang, Jinshui Pan, Yueyong Zhu

Ann Hepatol. 2025;30:101586

4966

Full text access

Share

4845

Association of sleep patterns and disorders with metabolic dysfunction-associated steatotic liver disease and liver fibrosis in contemporary American adults

Guannan Zong, Wangjia Mao, Ming Wen, Xiaoyun Cheng, Guanghui Liu

Ann Hepatol. 2025;30:101583

4845

Full text access

Share

4834

Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990-2021 to 2045

Chengxia Kan, Kexin Zhang, Yuqun Wang, Xiaofei Zhang, Chang Liu, Yanhui Ma, Ningning Hou, Na Huang, ... Xiaodong Sun

Ann Hepatol. 2025;30:101898

4834

Full text access

Share

4569

Mechanisms and therapeutic targets of mitochondria in the progression of metabolic dysfunction-associated steatotic liver disease

Chenyang Mu, Sijie Wang, Zenghan Wang, Jian Tan, Haozan Yin, Yuefan Wang, Zhihui Dai, Dongyang Ding, Fu Yang

Ann Hepatol. 2025;30:101774

4569

Full text access

Share

4565

cccDNA epigenetic regulator as target for therapeutical vaccine development against hepatitis B

Patricia Gita Naully, Marselina Irasonia Tan, Agustiningsih Agustiningsih, Caecilia Sukowati, Ernawati Arifin Giri-Rachman

Ann Hepatol. 2025;30:101533

4565

Full text access

Share

4550

Diagnostic performance of FibroTouch® in assessing hepatic steatosis and fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: An Asian experience

Thanikan Sukaram, Soe Thiha Maung, Yuda Chongpison, Tassanan Jaihan, Chonlada Phathong, Roongruedee Chaiteerakij

Ann Hepatol. 2025;30:101753

4550

Full text access

Share

4142

From gut to liver: Exploring the crosstalk between gut-liver axis and oxidative stress in metabolic dysfunction-associated steatotic liver disease

Mi Zhou, Jianyu Lv, Xinli Chen, Yujie Shi, Guanqun Chao, Shuo Zhang

Ann Hepatol. 2025;30:101777

4142

Full text access

Share

3931

A global comparison of hepatitis B & C drug pricing

Leah Yao, Xiaohan Ying, Getan Malik, Catherine Tsai, Arun B. Jesudian, Robert S. Brown Jr., Stephen E. Congly

Ann Hepatol. 2025;30:101928

3931

Full text access

Share

3675

The burden of hepatic encephalopathy and the use of albumin as a potential treatment

Jasmohan S. Bajaj, Enrico Pompili, Paolo Caraceni

Ann Hepatol. 2025;30:101751

3675

Full text access

Share

3607

Brain reserve in hepatic encephalopathy: Pathways of damage and preventive strategies through lifestyle and therapeutic interventions

Jacqueline Cordova-Gallardo, Andres Manuel Vargas-Beltran, Samantha Melanie Armendariz-Pineda, Jesus Ruiz-Manriquez, Javier Ampuero, Aldo Torre

Ann Hepatol. 2025;30:101740

3607

Full text access

Share

3563

Latin American association for the study of the liver (ALEH) guidance on preoperative care in liver transplantation: referral criteria, patient assessment, and waiting list management

Victoria Mainardi, Josefina Pages, Josemaría Menendez, Rodrigo Zapata, Luis Antonio Díaz, Sebastian Marciano, Fernando Cairo, Martin Padilla-Machaca, ... Alejandra Villamil

Ann Hepatol. 2025;30:101939

3563

Full text access

Share

3271

A landscape of liver cirrhosis and transplantation in Mexico: Changing leading causes and transplant as response

Icela Palma-Lara, María Guadalupe Ortiz-López, José Bonilla-Delgado, Juanita Pérez-Escobar, Ricardo Godínez-Aguilar, Claudia Luévano-Contreras, Ana María Espinosa-García, Javier Pérez-Durán, ... Carmen Palacios-Reyes

Ann Hepatol. 2025;30:101562

3271

Full text access

Share

3208

Clinical usefulness of an ultra-high-sensitivity hepatitis B surface antigen assay to determine the cessation of treatment for HBV reactivation

Takanori Suzuki, Akihiro Tamori, Kentaro Matsuura, Takako Inoue, Shigeru Kusumoto, Shinya Hagiwara, Haruka Sagi, Atsushi Kaneko, ... Yasuhito Tanaka

Ann Hepatol. 2025;30:101764

3208

Full text access

Share

3173

Semaglutide for the treatment of post transplantation diabetes mellitus in patients following liver transplantation is safe and effective

Daphne Bot, Bart van Hoek, Maarten E. Tushuizen

Ann Hepatol. 2025;30:101920

3173

Full text access

Share